ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2274

Evidence of Phospho-Degron Regulating Expression of Urate Secretory Transporter ABCG2

Alexis Hofherr1, Meng Li2, Michael Kottgen1 and Owen M. Woodward2, 1Nephrology, University of Freiburg Medical Center, Freiburg, Germany, 2Physiology, University of Maryland School of Medicine, Baltimore, MD

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: Gout and uric acid

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  ABCG2 is a high capacity urate secretory transporter of the renal proximal tubule. The common Q141K ABCG2 mutation causes gout in humans through an increased instability of the nucleotide-binding domain leading to enhanced degradation and reduced function.

Methods: Typical biochemical and cell biological techniques

Results:  Here, we found ABCG2 protein rescued from degradation with the proteasome inhibitor MG-132 is phosphorylated; raising the possibility that a phospho-degron regulates ABCG2 trafficking and expression. An in silicoanalysis of ABCG2 revealed a limited number of predicted phosphorylation sites, including S195, a serine conserved in the mammalian lineage. The upstream RXRXS represents a target motif for AKT1 and PKA, which both co-immunoprecipitated with ABCG2. Specifically, endogenous AKT1 pulled down both over expressed ABCG2 in HEK293 cells as well as endogenous ABCG2 in mouse kidney lysate. AKT1 and ABCG2 transcript co-localize in the proximal S2 segment of the mammalian nephron and inhibiting the AKT1 kinase cascade with PI3K inhibitor LY294002, or with growth factor receptor (RTK) inhibitor Vandetanib, dramatically up-regulated ABCG2 expression. Conversely, activating the AKT1 cascade with FBS down-regulated ABCG2 expression. Replacement of the S195 residue with a phosphomimetic aspartic acid resulted in significant reduction in ABCG2 expression, localization of ABCG2 to peri-nuclear compartments, and significant sensitivity to MG-132; confirming the S195 residue as a phospho-degron. Finally, a non-phosphorylatable S195A substitution led to the complete rescue of the Q141K gout mutant protein expression and trafficking.

Conclusion: Modeled ABCG2 structure indicates phosphorylation of the S195 residue may only be possible when the nucleotide-binding domains are separated, suggesting the S195 phospho-degron may be part of a novel regulatory mechanism for function and trafficking in ABC transporters. Funded by: American Heart Association 14SDG18060004 & Ardea BioSciences.


Disclosure: A. Hofherr, None; M. Li, None; M. Kottgen, None; O. M. Woodward, Ardea BioSciences, 2,AstraZeneca, 1.

To cite this abstract in AMA style:

Hofherr A, Li M, Kottgen M, Woodward OM. Evidence of Phospho-Degron Regulating Expression of Urate Secretory Transporter ABCG2 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/evidence-of-phospho-degron-regulating-expression-of-urate-secretory-transporter-abcg2/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2016

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-of-phospho-degron-regulating-expression-of-urate-secretory-transporter-abcg2/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology